197 related articles for article (PubMed ID: 2876495)
1. Neuroendocrine tumours of the gut: long-term therapy with the somatostatin analogue SMS 201-995.
Anderson JV; Bloom SR
Scand J Gastroenterol Suppl; 1986; 119():115-28. PubMed ID: 2876495
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
Williams G; Anderson JV; Williams SJ; Bloom SR
Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes.
Vinik AI; Tsai ST; Moattari AR; Cheung P; Eckhauser FE; Cho K
Am J Med; 1986 Dec; 81(6B):23-40. PubMed ID: 2879447
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995).
Kvols LK; Buck M; Moertel CG; Schutt AJ; Rubin J; O'Connell MJ; Hahn RG
Ann Intern Med; 1987 Aug; 107(2):162-8. PubMed ID: 2886085
[TBL] [Abstract][Full Text] [Related]
5. Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201-995.
Eriksson B; Oberg K; Andersson T; Lundqvist G; Wide L; Wilander E
Scand J Gastroenterol; 1988 May; 23(4):508-12. PubMed ID: 2898168
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin analogs in the management of gastrointestinal tumors.
Lamberts SW
Horm Res; 1988; 29(2-3):118-20. PubMed ID: 2900191
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.
Wood SM; Kraenzlin ME; Adrian TE; Bloom SR
Gut; 1985 May; 26(5):438-44. PubMed ID: 2860052
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin analogue SMS 201-995 long term therapy for vipoma.
Juby LD; Burke DA; Axon AT
Postgrad Med J; 1987 Apr; 63(738):287-9. PubMed ID: 2891127
[TBL] [Abstract][Full Text] [Related]
9. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors.
Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B
Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958
[TBL] [Abstract][Full Text] [Related]
10. [Mixed endocrine tumor of the pancreas (vipoma, glucagonoma). Treatment by somatostatin followed by one of its long-acting analogs].
Kaloustian E; Guillauseau PJ; Chayvialle JA; Veyssier P; Lallement PY; Latrive JP; Zylberait D; Lubetzki J
Presse Med; 1987 Dec; 16(44):2217-20. PubMed ID: 2893369
[TBL] [Abstract][Full Text] [Related]
11. Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours.
Lamberts SW; Pieters GF; Metselaar HJ; Ong GL; Tan HS; Reubi JC
Acta Endocrinol (Copenh); 1988 Dec; 119(4):561-6. PubMed ID: 2849276
[TBL] [Abstract][Full Text] [Related]
12. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours.
Dimitriadis GK; Weickert MO; Randeva HS; Kaltsas G; Grossman A
Endocr Relat Cancer; 2016 Sep; 23(9):R423-36. PubMed ID: 27461388
[TBL] [Abstract][Full Text] [Related]
13. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors.
Maton PN; Gardner JD; Jensen RT
Dig Dis Sci; 1989 Mar; 34(3 Suppl):28S-39S. PubMed ID: 2537716
[TBL] [Abstract][Full Text] [Related]
14. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome.
Souquet JC; Sassolas G; Forichon J; Champetier P; Partensky C; Chayvialle JA
Cancer; 1987 May; 59(9):1654-60. PubMed ID: 2435403
[TBL] [Abstract][Full Text] [Related]
15. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
Arnold R; Simon B; Wied M
Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
[TBL] [Abstract][Full Text] [Related]
16. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth.
Reubi JC
Acta Endocrinol (Copenh); 1985 May; 109(1):108-14. PubMed ID: 2860768
[TBL] [Abstract][Full Text] [Related]
17. Reduction of pituitary size by the somatostatin analogue SMS 201-995 in a patient with an islet cell tumour secreting growth hormone releasing factor.
Wilson DM; Hoffman AR
Acta Endocrinol (Copenh); 1986 Sep; 113(1):23-8. PubMed ID: 2876570
[TBL] [Abstract][Full Text] [Related]
18. Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue.
Ch'ng JL; Anderson JV; Williams SJ; Carr DH; Bloom SR
Br Med J (Clin Res Ed); 1986 Apr; 292(6526):981-2. PubMed ID: 2870758
[TBL] [Abstract][Full Text] [Related]
19. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
Gorden P; Comi RJ; Maton PN; Go VL
Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal endocrine tumours: medical management.
Arnold R; Frank M
Baillieres Clin Gastroenterol; 1996 Dec; 10(4):737-59. PubMed ID: 9113320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
